Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities
Frontiers in Cellular and Infection Microbiology · 19.11.2026 · 16
DOI: 10.3389/fcimb.2026.2000007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 19.11.2026. Verfasst von Ji-Hyun Yoon und 2 weiteren Autor:innen. Die Arbeit nennt 346 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Invasive fungal infections (IFIs) remain a major global health threat, particularly among immunocompromised patients. Current antifungals that target ergosterol biosynthesis, cell-wall assembly, and nucleic-acid synthesis are increasingly constrained by toxicity, drug-drug interactions, suboptimal pharmacokinetics, narrow spectra, and rising resistance. This review provides the transition from conventional antifungal agents to a next-generation, precision-oriented therapeutic landscape. In Part I, we expand the antifungal target repertoire beyond classical pathways to include emerging molecular nodes. Part II outlines principles for precision antifungal therapeutics, distinguishing pathogen-specific from broad-spectrum approaches and species-tailored regimens, and integrates rapid diagnostics into companion diagnostic frameworks. Part III surveys advanced therapeutic platforms, encompassing antifungal peptides, antibody-based agents, nucleic acid therapeutics, and engineered probiotic strategies. Part IV highlights drug-delivery innovations, including liposomal and nanoparticle carriers, stimuli-responsive systems, antibody- and ligand-targeted constructs, formulations optimized for biofilm penetration and intracellular delivery, and phage-inspired delivery, with AI-assisted design accelerating formulation optimization. Part V synthesizes combination strategies. Together, these advances define a conceptual framework for precision antifungal medicine that integrates pathogen profiling, host factors, pharmacogenomics, therapeutic drug monitoring, and multi-omics data to individualize therapy, overcome resistance, improve selectivity, and enhance clinical outcomes in IFIs.
Zitieren
APA
Yoon, J., Kim, Y., & Kim, K. (2026). Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.2000007
Vancouver
Yoon J, Kim Y, Kim K. Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.2000007
BibTeX
@article{Yoon2026,
author = {Yoon, Ji-Hyun and Kim, Yeo-Jin and Kim, Ki-Young},
title = {Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.2000007}
}
EUVIMED